ROS1 and non-small cell lung carcinoma: This study discovered that among 18 NSCLC patients with RET fusions treated with pemetrexed, there was a 45% objective response rate (ORR) and a median PFS of 19 months [36], These outcomes are on par with similar treatment regimens used for ROS1 fusion-positive and ALK-rearranged NSCLCs.